Medscape

FDA Approves Extended-Release Clonidine for Pediatric ADHD

October 7, 2010 — The US Food and Drug Administration (FDA) has approved clonidine hydrochloride, 0.1-mg and 0.2-mg, extended-release tablets (Kapvay; Shionogi Inc ...
MedPage Today

Clonidine Comparable to Morphine for Infants With Opioid Withdrawal

Length of treatment and neurobehavioral scores did not significantly differ between infants with prenatal opioid exposure randomized to either clonidine or morphine, researchers found. Among infants ...
Medscape

Clonidine as a First-line Sedative Agent After Neonatal Cardiac Surgery

Objectives: To determine the cardiovascular tolerance of clonidine used as a first-line sedative after cardiac surgery in small infants. Design: Retrospective chart review. Setting: A tertiary and ...
Business Wire

Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...
Business Wire

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...